HR positive + HER-2 negative	Male Breast Cancer	HR positive + HER-2 negative	Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
No biomarker	Male Breast Cancer	No biomarker	Male Breast Cancer	HER2 inhibitor Sensitive: A2 - Guideline HER2 inhibitor Sensitive : A2	HER2 inhibitor Sensitive: A2 - Guideline HER2 inhibitor Sensitive : A2
HR positive + HER-2 negative	Male Breast Cancer	HR positive + HER-2 negative	Male Breast Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
HR positive	Male Breast Cancer	HR positive	Male Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
HR positive	Male Breast Cancer	HR positive	Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
ER positive	Male Breast Cancer	ER positive	Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
PIK3CA mutation + HR positive + HER-2 negative	Male Breast Cancer	PIK3CA mutation + HR positive + HER-2 negative	Male Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
HR positive + HER-2 negative	Male Breast Cancer	HR positive + HER-2 negative	Male Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
HR positive + HER-2 negative	Male Breast Cancer	HR positive + HER-2 negative	Male Breast Cancer	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
HR positive + HER-2 negative	Male Breast Cancer	HR positive + HER-2 negative	Male Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3

Male Breast Cancer

Associations(10)

Associations
(10)